Northland Securities reiterated their buy rating on shares of ImmuPharma PLC (LON:IMM) in a research note published on Wednesday morning. Northland Securities currently has a GBX 171 ($2.12) target price on the stock.

Several other research analysts also recently weighed in on the stock. Panmure Gordon reaffirmed a buy rating and issued a GBX 100 ($1.24) target price on shares of ImmuPharma PLC in a report on Monday, October 24th. Northland Capital Partners began coverage on shares of ImmuPharma PLC in a report on Wednesday, July 20th. They issued a buy rating and a GBX 171 ($2.12) target price for the company.

ImmuPharma PLC (LON:IMM) opened at 37.00 on Wednesday. The stock’s 50 day moving average price is GBX 36.98 and its 200-day moving average price is GBX 35.59. ImmuPharma PLC has a 52 week low of GBX 19.10 and a 52 week high of GBX 48.88. The company’s market capitalization is GBX 41.28 million.

ImmuPharma PLC Company Profile

ImmuPharma plc (ImmuPharma) is a United Kingdom-based is a drug discovery and development company. Its research operations are in France. The Company is engaged in the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions, such as autoimmune diseases. ImmuPharma is engaged in developing drug candidates for five different medical conditions.

Receive News & Stock Ratings for ImmuPharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma PLC and related stocks with our FREE daily email newsletter.